Frazier Lifesciences Acquisition (FLACU) Stock Price, News & Analysis

Company Overview

Frazier Lifesciences Acquisition Corp (OTCMKTS: FLACU) is a special purpose acquisition company formed to pursue mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations or similar business combinations with one or more businesses in the life sciences sector. The company seeks to leverage the deep industry expertise of its sponsor to identify and partner with companies operating in pharmaceuticals, biotechnology, medical devices and related healthcare services. As a blank check vehicle, Frazier Lifesciences Acquisition does not currently generate operating revenues and holds the proceeds from its initial public offering in a trust account until a business combination is completed.

Incorporated in Delaware in October 2020, the company is sponsored by Frazier Healthcare Partners, a Seattle‐based private equity firm focused on investments in therapeutics, medical technology and specialty services. Frazier Healthcare Partners’ team brings extensive transaction experience and domain knowledge to the SPAC, positioning it to evaluate potential targets across North America and select international markets. The SPAC structure allows management to execute an acquisition with the benefit of public equity and the flexibility to negotiate strategic partnerships within the life sciences ecosystem.

With offices in Seattle, Washington, Frazier Lifesciences Acquisition Corp is governed by an independent board and led by executives drawn from healthcare investing and corporate development backgrounds. The company’s leadership team is tasked with sourcing opportunities, conducting due diligence and structuring a business combination that aligns with shareholder interests. Upon completion of a qualifying transaction, the combined entity is expected to leverage Frazier Healthcare Partners’ operating and financial resources to support growth and innovation in its chosen platform company.

Key Stats

• Today's Range: $8.07 to $10.80
• 50-Day Range: $9.50 to $9.50
• 52-Week Range: $8.07 to $10.80
• Volume: 18,300 shs
• Average Volume: 13,949 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:FLACU
• CIK: 1828326
• Web: www.frazierlifesciencesacquisition.com
• Phone: 206 621 7200
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A